|
Synonyms: LR12
Compound class:
Peptide
Comment: Nangibotide (LR12) is a 12 amino-acid synthetic peptide that was designed as an inhibitor of TREM1 receptor-mediated pro-inflammatory signalling (e.g., release of IL-1β and IL-8) [7]. It is a fragment of the the soluble TREM-like transcript-1 (TLT-1) derivative LR17 [2]. Nangibotide is intended to reduce excessive inflammatory responses and reduce tissue damage. It is a useful experimental tool for further investigations into the potential of TREM1 inhibition for the treatment of acute and chronic noninfectious inflammatory disorders such as myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
Nangibotide was the first TREM1 inhibitor to progress as a clinical candidate. |
| References |
|
1. Cuvier V, Lorch U, Witte S, Olivier A, Gibot S, Delor I, Garaud JJ, Derive M, Salcedo-Magguilli M. (2018)
A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. Br J Clin Pharmacol, 84 (10): 2270-2279. [PMID:29885068] |
|
2. Derive M, Bouazza Y, Sennoun N, Marchionni S, Quigley L, Washington V, Massin F, Max JP, Ford J, Alauzet C et al.. (2012)
Soluble TREM-like transcript-1 regulates leukocyte activation and controls microbial sepsis. J Immunol, 188 (11): 5585-92. [PMID:22551551] |
|
3. François B, Lambden S, Garaud JJ, Derive M, Grouin JM, Asfar P, Darreau C, Mira JP, Quenot JP, Lemarié J et al.. (2023)
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial. EClinicalMedicine, 60: 102013. [PMID:37350989] |
|
4. François B, Wittebole X, Ferrer R, Mira JP, Dugernier T, Gibot S, Derive M, Olivier A, Cuvier V, Witte S et al.. (2020)
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial. Intensive Care Med, 46 (7): 1425-1437. [PMID:32468087] |
|
5. Francois B, Lambden S, Gibot S, Derive M, Olivier A, Cuvier V, Witte S, Grouin JM, Garaud JJ, Salcedo-Magguilli M et al.. (2021)
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial. BMJ Open, 11 (7): e042921. [PMID:34233965] |
|
6. Neupane M, Kadri SS. (2023)
Nangibotide for precision immunomodulation in septic shock and COVID-19. Lancet Respir Med, 11 (10): 855-857. [PMID:37269869] |
|
7. Xu X, Cai L, Dang X, Han J, Kou Y, Rong C, Kou J. (2026)
Inhibition of TREM1 attenuates myocardial ischemia-reperfusion injury-induced cardiomyocyte pyroptosis by suppressing the activation of the NF-κB signaling pathway. PLoS One, 21 (1): e0340382. [PMID:41511954] |